Posted by Michael Wonder on 29 Apr 2026
Intellia Therapeutics initiates rolling submission of biologics license application to FDA for lonvoguran ziclumeran as a one time treatment for hereditary angioedema
27 April 2026 - Expect to complete BLA submission in second half of 2026; anticipate launch in first half of 2027, if approved.
Intellia Therapeutics today announced it has initiated a rolling submission of a biologics license application to the US FDA seeking approval of lonvoguran ziclumeran (formerly known as NTLA-2002) for hereditary angioedema.
